Key clinical point:
Major finding: Strong BCL2 expression was seen in 46% of secondary lymphomas, versus just 4% of primary cutaneous follicular center-cell lymphomas (P = .001).
Study details: A comparative study evaluating clinicopathologic and genetic features in a series of patients, including 59 with PCFCL and 22 with SCFL.
Disclosures: Investigators did not report disclosures related to the research.
Servitje O et al. J Cutan Pathol. 2019;46:182-9.